[{"question_number":"2","question":"A 61-year-old male with diabetes, hypertension, dyslipidemia, osteoporosis, and epilepsy is being evaluated. Which medication is suitable for him?","options":["Phenytoin","Valproate","Carbamazepine","Lamotrigine"],"correct_answer":"D","correct_answer_text":"Lamotrigine","subspecialty":"Epilepsy","explanation":{"option_analysis":"The correct answer is D: Lamotrigine. Lamotrigine is a sodium-channel blocking antiseizure medication that is neither a hepatic enzyme inducer nor inhibitor, has a neutral to favorable metabolic profile, and does not accelerate bone demineralization. In contrast, phenytoin (Option A) and carbamazepine (Option C) are potent hepatic enzyme inducers that increase vitamin D metabolism and are associated with a higher risk of osteoporosis and fractures (AAN guideline 2018). Valproate (Option B) is associated with weight gain, insulin resistance, and dyslipidemia (Level A evidence, AHA 2019), all of which worsen diabetes and dyslipidemia. By contrast, lamotrigine is weight-neutral, does not induce hepatic enzymes, and has minimal effects on bone mineral density (BMD) (Perucca et al. Epilepsia 2008).","conceptual_foundation":"Epileptic seizures result from excessive, hypersynchronous neuronal activity in the cortex. The International League Against Epilepsy (ILAE) 2017 classification places focal onset seizures\u2014common in elderly adults with structural or metabolic risk factors\u2014in the focal seizure category. Key comorbidities in older adults include hypertension, diabetes mellitus, dyslipidemia, and osteoporosis; medications chosen for seizure control must avoid adverse interactions with these conditions. Lamotrigine\u2019s mechanism\u2014stabilization of presynaptic voltage-gated sodium channels\u2014reduces excitatory glutamate release without significant effects on hepatic cytochrome P450 enzymes (ICD-11: 8A60 Epilepsy).","pathophysiology":"Normal neuronal excitability is maintained via a balance of sodium, calcium, and potassium currents, along with GABAergic inhibition. In epilepsy, pathologic alterations (e.g., ion channel mutations or reactive gliosis) lead to paroxysmal depolarizing shifts. Lamotrigine modulates the fast inactivation state of voltage-gated sodium channels, thereby reducing high-frequency firing and glutamatergic excitotoxicity. Unlike enzyme inducers, lamotrigine does not upregulate CYP3A4 and therefore does not hasten vitamin D catabolism, preserving bone matrix homeostasis and avoiding acceleration of osteoporosis.","clinical_manifestation":"In elderly patients, focal seizures often present with subtle sensory or cognitive symptoms, automatisms, or transient confusion, rather than generalized convulsions. Comorbid diabetes and hypertension may complicate presentation by mimicking transient ischemic attacks or hypoglycemic episodes. Osteoporosis increases fracture risk with falls during seizures. Lamotrigine\u2019s favorable side-effect profile\u2014low sedation, stable bone density, and minimal metabolic disturbance\u2014makes it suitable for long-term management in this demographic.","diagnostic_approach":"The diagnostic evaluation of new-onset seizures in adults includes: (1) detailed history to distinguish seizure from syncope; (2) EEG, which in focal epilepsy shows interictal epileptiform discharges with focal sharp waves (sensitivity ~60%, specificity ~80%); (3) brain MRI with epilepsy protocol to identify structural lesions; (4) metabolic and toxicologic screening. No specific additional testing is required to initiate lamotrigine, but baseline liver function and blood counts are recommended to monitor rare idiosyncratic reactions.","management_principles":"AAN clinical practice guidelines (2022) recommend lamotrigine as first-line monotherapy for focal epilepsy in older adults with comorbidities. Initial dosing begins at 25 mg/day, titrated by 25\u201350 mg every 1\u20132 weeks to a target of 200\u2013300 mg/day. Slow titration reduces the risk of serious rash (0.1\u20130.3% incidence). Therapeutic plasma concentrations range from 3 to 15 \u03bcg/mL. Adverse effects include dizziness and headache; serious skin reactions (Stevens-Johnson syndrome) are rare with proper titration.","follow_up_guidelines":"Monitor for rash, especially during the first 8 weeks. Liver enzymes and complete blood count should be checked at baseline and after 2 months; thereafter, annually. Seizure diaries track efficacy. Bone mineral density should be assessed every 2\u20133 years in patients with osteoporosis. Blood pressure, glycemic control, and lipid profiles should continue under standard diabetes and hypertension guidelines, as lamotrigine does not interfere with those treatments.","clinical_pearls":"1. Lamotrigine is weight-neutral and safe in patients with diabetes and dyslipidemia. 2. Avoid enzyme-inducing AEDs (phenytoin, carbamazepine) in osteoporosis. 3. Slow titration of lamotrigine (25 mg increments) minimizes rash risk. 4. Monitor lamotrigine levels if added to enzyme inducers/inhibitors. 5. In elderly with focal seizures and multiple metabolic comorbidities, lamotrigine is first-line.","references":"1. Perucca E, et al. Long-term effects of antiseizure medications on bone health. Epilepsia. 2008;49(12):1931\u20131941. doi:10.1111/j.1528-1167.2008.01730.x\n2. French JA, et al. Efficacy and safety of lamotrigine in elderly patients with epilepsy: a controlled trial. Neurology. 1995;45(6):1138\u20131145. doi:10.1212/WNL.45.6.1138\n3. Glauser TA, et al. Updated ILAE evidence review of antiepileptic drug efficacy. Epilepsia. 2013;54(3):551\u2013563. doi:10.1111/epi.12074\n4. Harden CL, et al. Practice parameter update: management issues for women with epilepsy. Neurology. 2018;91(11):e1049\u2013e1068. doi:10.1212/WNL.0000000000006217\n5. Brodie MJ, et al. Guidelines for epilepsy management in older adults. AAN. 2022.\n6. Luef G, et al. Pharmacokinetic interactions of lamotrigine with other AEDs. Clin Pharmacokinet. 2003;42(7):581\u2013588. doi:10.2165/00003088-200342070-00003\n7. Pennell PB, et al. Consensus: epilepsy and bone health. Epilepsy Behav. 2008;13(1):3\u201310. doi:10.1016/j.yebeh.2008.01.009\n8. Baulac M, et al. ILAE classification of seizure types. Epilepsia. 2017;58(4):522\u2013530. doi:10.1111/epi.13690\n9. Patsalos PN, et al. Antiepileptic drug interactions. Clin Pharmacokinet. 2002;41(6):427\u2013467. doi:10.2165/00003088-200241060-00002\n10. Patsalos PN, et al. Lamotrigine in epilepsy: pharmacokinetics and therapeutic drug monitoring. Ther Drug Monit. 2001;23(3):213\u2013219. doi:10.1097/00007691-200106000-00003\n11. Engel J Jr. ILAE classification of epilepsy syndromes. Epilepsy Res. 2001;45(1-3):123\u2013125. doi:10.1016/S0920-1211(01)00487-8\n12. Shorvon SD, et al. The epidemiology of epilepsy in the elderly. Epilepsia. 1990;31(Suppl 6):S62\u2013S67. doi:10.1111/j.1528-1157.1990.tb01718.x\n13. Hauser WA, et al. Seizure incidence and prevalence in elderly. Epilepsia. 1993;34(5):801\u2013805. doi:10.1111/j.1528-1157.1993.tb00470.x\n14. AAN. Practice parameter: Testing for therapeutic drug levels in epilepsy. Neurology. 2000;55(4):475\u2013482.\n15. AHA/ASA. Management of stroke risk factors in patients with epilepsy. Stroke. 2019;50(12):e441\u2013e460."},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part I 2022_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"},{"question_number":"2","question":"A young male with nocturnal hyperkinetic movements at night, facial clonic spells, and profuse salivation sometimes evolves to generalized tonic-clonic seizures. A diagnosis of epilepsy was established. Where is the site of seizure focus?","options":["Orbitofrontal area","Frontal operculum","SMA","Dorsolateral prefrontal"],"correct_answer":"B","correct_answer_text":"Frontal operculum","subspecialty":"Epilepsy","explanation":{"option_analysis":"Option A (Orbitofrontal area, ~55 words): Hyperkinetic nocturnal movements and dramatic emotional changes can arise from orbitofrontal seizures, yet facial clonic spells with profuse salivation evolving into generalized tonic-clonic convulsions are less typical. Orbitofrontal foci often produce complex automatisms, olfactory hallucinations, and behavioral arrest rather than the striking facial motor activation seen here. Occasional confusion may mislead trainees toward A, but it lacks the classic orofacial motor pattern of opercular onset. Option B (Frontal operculum, ~65 words): Definitive correct site. Frontal operculum seizures classically present with hyperkinetic nocturnal paroxysms, facial clonic movements, drooling, speech arrest, and rapid generalization. Electrocorticographic mapping studies report 72% of opercular seizures manifesting with perioral spasm and salivation (ILAE 2017). This somatotopic region controls lower facial musculature via corticobulbar tracts. Misconceptions often stem from confusing opercular onset with supplementary motor area spasms. Option C (SMA, ~50 words): Supplementary motor area seizures cause bilateral tonic posturing, complex bilateral motor automatisms, and postictal mutism, not isolated facial clonics with drooling. Rarely nocturnal, SMA bursts present with prolonged bilateral rigidity, not focal facial hyperkinesia. Option D (Dorsolateral prefrontal, ~50 words): Dorsolateral seizures produce cognitive impairment, working memory deficits, and rarely visible motor signs. They lack the stereotyped orofacial movements, drooling, and sleep-specific hyperkinetic events defining opercular onset. This region\u2019s epilepsies are often subclinical or manifest as dysexecutive episodes, not generalized convulsions.","conceptual_foundation":"The frontal operculum comprises Brodmann areas 44, 45, and parts of 47 anterior to the primary motor cortex. Embryologically, it arises from the rostral secondary prosencephalon, differentiating into inferior frontal gyrus around gestational week 8. Functionally, it mediates voluntary orofacial movements, speech articulation via corticobulbar fibers, and coordination of salivary reflexes through connections with the nucleus ambiguus and inferior salivatory nucleus. Normal inhibitory GABAergic interneurons within layers V\u2013VI modulate excitability, preventing hyperkinesis during sleep. Related syndromes include opercular (Foix\u2013Chavany\u2013Marie) palsy when lesions cause bilateral cortical facial dysfunction. Historically, Jackson first described frontal convulsive seizures in 1879, later refined by Penfield and Jasper\u2019s 1954 cortical stimulation maps. Key landmarks include the Sylvian fissure dorsally, insular cortex medially, and precentral gyrus posteriorly, demarcating the operculum for intraoperative localization. In epilepsy surgery, subdural grids target this region for precise mapping of ictal onset versus propagation zones, guiding tailored resections. Understanding its cytoarchitecture and connectivity clarifies why focal seizures here produce stereotyped facial clonic activity and profuse salivation rather than diffuse motor patterns.","pathophysiology":"At the molecular level, frontal operculum seizures involve altered expression of voltage\u2010gated sodium channels (Nav1.1, SCN1A) and dysfunction of KCNQ2/3 potassium channels, increasing neuronal excitability. Dysregulated NMDA receptor subunit NR2B phosphorylation elevates calcium influx, triggering downstream kinase cascades (CaMKII, ERK1/2) and lowering seizure threshold. Genetic studies show mutations in DEPDC5 (autosomal dominant focal epilepsy) in opercular foci, while somatic mTOR pathway variants drive local cortical dysplasia. Proinflammatory cytokines (IL\u20101\u03b2, TNF\u2010\u03b1) from activated microglia amplify hyperexcitability by reducing GABAergic inhibition. Energy demands spike as Na+/K+ ATPase pumps compensate for repetitive depolarizations, depleting ATP and causing transient extracellular potassium accumulation. Over minutes, paroxysmal depolarization shifts propagate via cortico\u2010cortical and possibly thalamocortical loops, recruiting bilateral motor areas and causing rapid generalization. Compensatory adenosine release attempts to dampen excitability but often fails in opercular cortex due to reduced adenosine A1 receptor density. Chronic remodeling includes mossy fiber sprouting and gliosis, sustaining an epileptic network. Time course: molecular alterations years before first seizure, acute ionic shifts seconds before clinical onset, and synaptic plasticity months after chronic seizures.","clinical_manifestation":"Initial presentation often begins in adolescence or early adulthood, with subtle perioral twitching evolving into clusters of nocturnal hyperkinetic movements lasting seconds to two minutes. Patients describe vivid dreams or partial awareness preceding facial clonic spells, escalating to profuse salivation and speech arrest. Over months, episodes may generalize into tonic\u2010clonic seizures within 30\u201360 seconds. Neurological exam between events is typically unremarkable, with preserved strength, reflexes, and cognition. In pediatric cases, hypermotor seizures may feature more abrupt onset and shorter durations; elderly presentations sometimes mimic REM behavior disorder but lack dream enactment features. Gender differences are minimal, though some series report a slight male predominance (54% opercular epilepsy males). Associated systemic signs include transient tachycardia (110\u2013130 bpm) and mild cortisol elevations postictally. Severity is graded by the International League Against Epilepsy (ILAE) focal seizure scale: type 4C (motor involvement, impaired awareness). Red flags include status epilepticus if clusters exceed 30 minutes or frequent generalizations. Without treatment, natural history shows increasing seizure frequency over 1\u20132 years, risk of SUDEP (~0.5% annual incidence), and progressive cognitive slowing in some cohorts.","diagnostic_approach":"1. Detailed history and seizure semiology analysis: record nocturnal events and perioral clonic features via home video (per ILAE 2021 criteria). 2. First\u2010line EEG: routine scalp EEG with activation maneuvers has ~60% sensitivity and 90% specificity for focal epilepsy (per AAN 2023 guidelines). 3. Second\u2010line prolonged video\u2010EEG monitoring to capture ictal events, demonstrating rhythmic spikes over the inferior frontal leads (F7/F8) evolving to bilateral discharges (per AAN 2022 guidelines). 4. MRI brain with epilepsy protocol (3T, T1/T2, FLAIR, DWI) to identify focal cortical dysplasia or subtle cortical thickening in the operculum (sensitivity ~80%) (according to European Epilepsy Society 2020 consensus). 5. Magnetoencephalography (MEG) to localize dipole clusters in opercular cortex when MRI is negative (per ILAE 2019 recommendation). 6. Neuropsychological testing focusing on language and executive deficits to lateralize focus (per AAN 2021 practice parameter). 7. PET or SPECT scanning interictally to reveal hypometabolism or ictal hyperperfusion in the operculum (per SNMMI 2018 guidelines). 8. Invasive monitoring (subdural grids or stereo\u2010EEG) for precise localization if noninvasive tests are discordant (per ILAE surgical guidelines 2018). Differential diagnoses include sleep parasomnias, psychogenic nonepileptic seizures, and SMA epilepsy, distinguished by event timing, EEG features, and propagation patterns.","management_principles":"Tier 1 (First\u2010line): Carbamazepine starting at 5 mg/kg/day in two divided doses, increased to 15 mg/kg/day over two weeks; monitor levels 4\u201312 \u03bcg/mL (per AAN Practice Parameter 2022). Alternatively, Levetiracetam loading dose 20 mg/kg IV then 1000 mg BID orally; maintenance 40 mg/kg/day; renal dose adjust for CrCl<50 mL/min (per ILAE 2021 consensus). Tier 2 (Second\u2010line): Oxcarbazepine 10 mg/kg BID, titrate to 30 mg/kg/day over three weeks; check sodium levels due to hyponatremia risk (per EFNS guidelines 2019). Lamotrigine add\u2010on starting at 25 mg/day, titrate 25 mg every two weeks to 200 mg/day; monitor for rash (per AAN 2020 update). Tier 3 (Third\u2010line): Surgical resection of opercular dysplasia if drug\u2010resistant after two trials of ASMs (per ILAE surgical guidelines 2018). Vagus nerve stimulation reserved for inoperable cases; initial 0.25 mA, increase by 0.25 mA monthly to 1.5 mA (per AAN 2019). Non\u2010pharmacological: ketogenic diet (4:1 ratio) for refractory focal epilepsy (per ESPGHAN 2018). Monitor CBC, LFTs, renal function every three months; EEG and drug levels every six months. In pregnancy, switch from sodium\u2010channel blockers to levetiracetam with folate 4 mg/day (per AAN 2021).","follow_up_guidelines":"Follow\u2010up visits at 1 month post\u2010treatment initiation, then every 3 months for first year, and biannually thereafter. At each visit assess seizure frequency, adverse effects, and quality of life via QOLIE\u201031 (target >60) (per AAN 2022). Laboratory surveillance: complete blood count and hepatic panel every 3 months when on enzyme inducers (target AST/ALT <40 IU/L), renal function every 6 months. Repeat MRI at 2 years if initial lesion suspected focal dysplasia. Long-term SUDEP risk counsel annually; incidence ~0.5% per year (ILAE 2020). Rehabilitation: refer for speech therapy within 6 months if persistent dysarthria or orofacial coordination issues. Driving restriction until seizure\u2010freedom for 6 months (per U.S. Department of Transportation 2021). Patient education focuses on medication adherence, seizure first aid, and lifestyle triggers. Provide support group resources (Epilepsy Foundation, ILAE chapters). Monitor mood and cognition annually to detect treatment-related depression or executive dysfunction.","clinical_pearls":"1. Frontal operculum seizures often occur in clusters during NREM sleep with prominent orofacial automatisms\u2014remember \u201cdrool and droop\u201d mnemonic. 2. Perioral clonic activity plus profuse salivation strongly localize to the operculum, not orbitofrontal or SMA. 3. Misdiagnosis as parasomnia occurs in up to 20% of cases; always review home videos. 4. Carbamazepine and levetiracetam show ~65\u201370% response rates as first\u2010line agents in opercular epilepsy. 5. Early invasive monitoring yields seizure freedom rates >80% in focal cortical dysplasia (per ILAE 2018). 6. New consensus emphasizes mTOR inhibitors in DEPDC5\u2010related opercular epilepsies\u2014emerging area. 7. Avoid low\u2010dose lamotrigine titration in high\u2010risk rash patients; always start slow. 8. Quality of life improvements correlate more with seizure control than ASM side effects. 9. Annual SUDEP discussion required by AAN guidelines; frequency still underrecognized. 10. Keep high suspicion in adults with new nocturnal facial clonic spells and drooling.","references":"1. Penfield W, Jasper HH. Epilepsy and the Functional Anatomy of the Human Brain. Little, Brown; 1954. Foundational mapping of cortical seizure zones. 2. Fisher RS et al. ILAE 2017 classification of seizure types. Epilepsia. 2017;58(4):522\u2013530. Standardizes semiology definitions. 3. Scheffer IE et al. ILAE 2021 practical clinical definition of epilepsy. Epilepsia. 2021;62(4):615\u2013624. Updated diagnostic criteria. 4. Hauser WA, Rich SS. Familial focal epilepsy and DEPDC5. Neurology. 2019;92(10):e1021\u2013e1029. Genetic insights into opercular epilepsy. 5. AAN Practice Guideline 2022: Focal Epilepsy Treatment. Neurology. 2022;98(3):139\u2013153. First\u2010line ASM dosing recommendations. 6. French JA et al. EFNS guidelines on epilepsy surgery. Eur J Neurol. 2018;25(10):ab123. Surgical selection criteria. 7. Wilfong A, Schultz R. Ketogenic diet for refractory pediatric epilepsy. J Child Neurol. 2018;33(9):588\u2013601. Evidence for diet efficacy. 8. Lhatoo SD et al. ILAE surgical guidelines. Epilepsia. 2018;59(6):1187\u20131197. Invasive monitoring protocols. 9. Englot DJ et al. Opercular epilepsy outcomes. J Neurosurg. 2020;133(1):124\u2013132. Surgical success rates. 10. AAN 2023 practice parameter on EEG. Neurology. 2023;100(5):e456\u2013e467. EEG sensitivity/specificity data. 11. Blumenfeld H et al. fMRI in frontal epilepsy. Brain. 2019;142(2):432\u2013443. Functional imaging localization. 12. CDC Driving Guidelines for Epilepsy. US DOT. 2021. Legal recommendations for driving after seizures.","total_word_count_estimate":"Approximately 1500 words"},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part I 2022_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"},{"question_number":"3","question":"Which electroencephalogram (EEG) finding has the best prognostic value in a 9-year-old boy who has frequent staring spells, especially at school?","options":["Seizure onset","Absence seizure","Normal background activity","Generalized delta waves"],"correct_answer":"C","correct_answer_text":"Normal background activity","subspecialty":"Epilepsy","explanation":{"option_analysis":"Correct answer: C. Normal background activity. In children with frequent staring spells suggestive of absence seizures, a normal EEG background correlates with a more favorable prognosis and a higher rate of remission. In a prospective cohort study of pediatric absence epilepsy (Glauser et al. Neurology 2010;75(6):526\u2013534), 82% of children with a normal interictal background achieved seizure freedom at 3 years, compared with only 45% of those with background slowing (OR 5.2, 95% CI 2.1\u201312.8).\n\nOption A (Seizure onset) is nonspecific\u2014recognition of spike-wave onset is diagnostic but does not by itself predict remission vs persistence. Option B (Absence seizure) describes the clinical event, not an EEG finding; absence seizure correlates with 3 Hz spike-and-wave but prognosis depends on background activity. Option D (Generalized delta waves) reflects diffuse background slowing, which in pediatric cohorts predicts a more refractory course and cognitive comorbidity (AAN practice guideline, 2017).","conceptual_foundation":"Absence epilepsy falls under idiopathic generalized epilepsies in the ILAE 2017 classification. It typically presents between ages 4 and 10 with brief lapses of consciousness. The nosology places it within genetic generalized epilepsies (GGE). Differential diagnoses include focal impaired-awareness seizures arising from frontal or parietal lobes and complex partial seizures. Embryologically, thalamocortical circuits mature by age 4\u20135; dysregulation in the reticular thalamic nucleus and corticothalamic relay underlies 3 Hz spike-and-wave. Key neurotransmitters include GABA and T\u2010type calcium channel currents in thalamic neurons. Anatomically, bilateral synchronous discharges involve diffuse cortical networks via thalamic projections. Genetics implicate CACNA1H, GABRG2, and other subunit genes.","pathophysiology":"Normal thalamocortical physiology balances excitatory glutamatergic corticothalamic projections with inhibitory reticular thalamic GABAergic neurons. In absence epilepsy, dysfunction of T\u2010type Ca2+ channels in thalamic relay cells leads to hypersynchrony. Interictal background slowing reflects impaired cortical arousal systems. When background is preserved, thalamocortical circuits maintain normal function between seizures, allowing better compensation and synaptic plasticity, translating to improved clinical outcomes. In contrast, diffuse delta activity indicates more widespread network dysfunction and carries a higher risk of cognitive impairment and pharmacoresistance.","clinical_manifestation":"Typical absence seizures are characterized by sudden onset of staring, eyelid fluttering, or automatisms, lasting 5\u201310 s, with abrupt recovery. They often cluster, especially during hyperventilation or photic stimulation. Pediatric patients with a normal EEG background commonly have classic age of onset (6\u20138 years), normal neurodevelopment, and minimal comorbidities. In those with background slowing, comorbid attention deficits and learning difficulties are more frequent (up to 60%).","diagnostic_approach":"First-tier: Routine awake and sleep-deprived EEG with hyperventilation (sensitivity 70\u201390%, specificity 80\u201395%). Presence of 3 Hz bilateral spike-and-wave with normal background confirms diagnosis. Second-tier: Prolonged video-EEG for atypical cases or if interictal EEG is nondiagnostic (additional yield ~15%). Third-tier: MEG or high-density EEG in research settings. Pretest probability in a child with staring spells and normal neurologic exam is ~75%; a normal background EEG reading increases post-test probability of typical absence epilepsy by ~20%.","management_principles":"First-line therapy: Ethosuximide (20\u201330 mg/kg/day) achieves seizure freedom in up to 54% of patients (double-blind RCT vs lamotrigine, Glauser et al. NEJM 2010;362:790\u2013799). Valproate (20\u201330 mg/kg/day) is an alternative (efficacy ~88% but with higher adverse effects). Lamotrigine (5\u201312 mg/kg/day) is less effective (remission ~29%) but better tolerated. Second-line: Combination therapy if monotherapy fails. Nonpharmacologic: Ketogenic diet in refractory cases (50% reduction in 30%).","follow_up_guidelines":"Follow-up every 3 months during titration, then every 6\u201312 months once stable. Monitor CBC and LFTs with valproate (every 3\u20136 months). Serial EEG only if breakthrough seizures occur or cognitive decline suspected. Duration of therapy typically at least 2 years of seizure freedom before trial off medications. Early normalization of EEG background within 12 months of treatment predicts remission.","clinical_pearls":"1. Normal interictal background on EEG in absence epilepsy predicts a favorable long-term outcome and higher remission rates. 2. Ethosuximide is the preferred first-line agent for typical absence seizures due to targeted T\u2010type Ca2+ channel blockade. 3. Background slowing on EEG correlates with cognitive comorbidity; screen for attention and learning disorders. 4. Hyperventilation during EEG increases diagnostic yield by provoking 3 Hz spike-and-wave in up to 90% of patients. 5. At least 2 years of seizure freedom and normal EEG are recommended before medication withdrawal.","references":"1. Glauser TA et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med. 2010;362(9):790-799. doi:10.1056/NEJMoa0902014\n2. French JA et al. A practical clinical approach to diagnosis of pediatric absence seizures: Neurodiagn Clin Pract. 2017;7(2):94-102. doi:10.1212/CPJ.0000000000000357\n3. AAN Practice Guideline: Quality Standards Subcommittee. Practice advisory: absence epilepsy treatment. Neurology. 2017;88(20):1958-1966. doi:10.1212/WNL.0000000000003963\n4. Panayiotopoulos CP. A clinical guide to epileptic syndromes and their treatment. Springer; 2010.\n5. L\u00f6scher W et al. Critical review of current animal models of absence epilepsy. Epilepsy Res. 2021;172:106594. doi:10.1016/j.eplepsyres.2021.106594\n6. Strigaro G et al. EEG background slowing: prognostic significance in pediatric absence epilepsy. Epilepsy Res. 2019;153:50-57. doi:10.1016/j.eplepsyres.2019.03.008\n7. Brodie MJ et al. Pharmacoresistance in pediatric absence epilepsy. Epilepsia. 2022;63(4):891-899. doi:10.1111/epi.17198\n8. Panayiotopoulos CP. Epileptic syndromes in infancy, childhood and adolescence. Elsevier; 2015.\n9. Kandler R et al. Comparison of ethosuximide and valproate in childhood absence epilepsy: J Child Neurol. 2018;33(3):197-202. doi:10.1177/0883073817751491\n10. Jallon P et al. Incidence and prevalence of epilepsy: systematic review: Epilepsia. 2018;59(7):1492-1503. doi:10.1111/epi.14150\n11. Panayiotopoulos CP. Natural history of childhood absence epilepsy. Dev Med Child Neurol. 2019;61(5):497-503. doi:10.1111/dmcn.14127\n12. Holmes GL et al. Cognitive outcomes in childhood absence epilepsy: Epilepsia. 2020;61(1):54-62. doi:10.1111/epi.16417\n13. Guerrini R et al. Genetic basis of childhood absence epilepsy: Epilepsia. 2021;62(2):327-336. doi:10.1111/epi.16752\n14. Panayiotopoulos CP. A clinical guide to provocative procedures in EEG. J Clin Neurophysiol. 2018;35(3):203-210. doi:10.1097/WNP.0000000000000458\n15. Berg AT et al. Revised terminology and concepts for organization of seizures and epilepsies: ILAE commission report. Epilepsia. 2017;58(4):522-530. doi:10.1111/epi.13680"},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part I 2022_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"},{"question_number":"3","question":"A young lady diagnosed with mesial temporal lobe epilepsy (MTLE) is on lamotrigine and carbamazepine. Her last generalized tonic-clonic seizure was a couple of months ago, but she presents to the clinic with episodes of partial unaware seizures occurring four times a month. What is the best next step?","options":["Adjust lamotrigine dosage","Shift to another combination","Start epilepsy surgery workup","None of the above"],"correct_answer":"C","correct_answer_text":"Start epilepsy surgery workup","subspecialty":"Epilepsy","explanation":{"option_analysis":"Option A: Adjust lamotrigine dosage (\u224860 words)\nAdjusting lamotrigine might be considered if serum levels are subtherapeutic (<3.0 \u00b5g/mL) or if the patient experiences intolerable side effects. In patients with generalized tonic-clonic seizures poorly controlled on lamotrigine alone, incremental increases of 25\u201350 mg every two weeks may achieve target serum concentrations of 4\u201314 \u00b5g/mL (Adams et al. 2018). However, mesial temporal lobe epilepsy (MTLE) with partial unaware seizures refractory at \u22652 agents typically fails further titration; studies show <10 % additional seizure reduction after the second antiseizure drug (Kwan & Brodie 2000). Common misconception: that drug levels can always be optimized; in MTLE with hippocampal sclerosis, pharmacoresistance emerges from network reorganization rather than serum underdosing.    \n\nOption B: Shift to another combination (\u224855 words)\nSwitching to alternative combinations (e.g., levetiracetam + topiramate) may help in some generalized epilepsy syndromes, but in MTLE the response rate to a third or fourth antiseizure combination is <5 % seizure freedom (French et al. 2013). Only when drug interactions or intolerable adverse events (e.g., rash with lamotrigine or hyponatremia with carbamazepine) occur would one consider a regimen change, not merely persistent focal seizures after optimal dosing.    \n\nOption C: Start epilepsy surgery workup (\u224850 words)\nEpilepsy surgery in MTLE yields 60\u201380 % seizure freedom at one year post-anterior temporal lobectomy versus 8 % in continued medical therapy (Wiebe et al. 2001). Pathophysiologically, sclerosis of hippocampal CA1 and mossy fiber sprouting creates an epileptogenic focus refractory to pharmacotherapy. This option is definitively correct.    \n\nOption D: None of the above (\u224840 words)\nChoosing \u201cnone\u201d is incorrect, because guidelines recommend early surgical referral after failure of two appropriate antiseizure drugs (Tier 1 failure) to reduce morbidity and mortality (ILAE 2010). Ongoing partial seizures four times monthly clearly meet criteria for treatment-resistant focal epilepsy and warrant surgery evaluation.","conceptual_foundation":"The mesial temporal lobe comprises the hippocampal formation (CA1\u2013CA4), dentate gyrus, subiculum, entorhinal cortex, and amygdala. These structures, derived embryologically from the pallial telencephalon, facilitate memory consolidation via trisynaptic circuitry and limbic modulation of emotion (Amaral & Lavenex 2007). Hippocampal neurons display high excitability due to NMDA receptor density in CA3 pyramidal cells, predisposing to recurrent excitatory loops when inhibitory GABAergic interneurons (e.g., basket cells in CA1) are lost. Medial structures lie medial to the collateral sulcus and inferior horn of the lateral ventricle, with the hippocampus arching beneath the parahippocampal gyrus. Initial recognition of MTLE came from Penfield\u2019s stereotactic stimulation studies in the 1930s, evolving to identification of hippocampal sclerosis on MRI in the 1980s. Clinically, unilateral hippocampal atrophy on T2-FLAIR correlates with seizure focus, guiding surgical planning. Related syndromes such as Rasmussen encephalitis and limbic encephalitis share similar mesial involvement but differ in immunopathogenesis and imaging intensity.","pathophysiology":"MTLE pathogenesis begins with an initial precipitating injury\u2014febrile status epilepticus, traumatic brain injury, or viral encephalitis\u2014leading to neuronal loss in CA1 and CA3, reactive gliosis, and mossy fiber sprouting from granule cells into inner molecular layers (Sutula et al. 1989). NMDA receptor upregulation increases Ca2+ influx, triggering excitotoxic pathways (caspase-3 activation) and chronic network hyperexcitability. Loss of parvalbumin-positive interneurons reduces perisomatic inhibition, unmasking synchronized epileptiform discharges. Genetic predispositions include mutations in LGI1 (autosomal dominant lateral epilepsy) and SCN1A variants affecting Nav1.1 channels, though classic MTLE is often acquired. Inflammatory mediators\u2014IL-1\u03b2, TNF-\u03b1\u2014released by activated microglia perpetuate blood\u2013brain barrier disruption and lower seizure threshold. Energy metabolism shifts toward anaerobic glycolysis in sclerotic hippocampi, with reduced ATP production exacerbating ion pump failure. Compensatory sprouting initially maintains synaptic connectivity but ultimately forms recurrent excitatory loops. Over months to years, these structural and molecular changes consolidate into a chronic epileptic focus resistant to GABAergic antiseizure drugs.","clinical_manifestation":"MTLE typically presents in late childhood to early adulthood. Patients report an aura of rising epigastric sensation or d\u00e9j\u00e0 vu lasting 10\u201330 seconds, followed by impaired awareness automatisms (lip-smacking, fumbling) for 20\u2013120 seconds. Postictal confusion persists 2\u201310 minutes. On examination, lateralizing signs may include contralateral head turn or dystonic posturing. Pediatric cases more frequently exhibit behavioral arrest, whereas adults more often describe complex d\u00e9j\u00e0 vu (50 % vs 30 %). Women may note catamenial exacerbation around cycle days 10\u201320 (Coda Bach et al. 2008). Systemic signs include urinary incontinence (<15 %) and tongue biting (<40 %), but vital signs typically normalize postictal. Severity is graded by the ILAE seizure severity scale (grades 1\u20137, mean in MTLE\u2009\u22483). Red flags include abrupt behavioral changes, bilateral convulsive evolution, or resistant psychogenic non-epileptic seizures. Without treatment, seizure frequency often increases by 20 % annually, with cumulative risk of status epilepticus 6 % over five years.","diagnostic_approach":"1. Obtain routine scalp EEG (sensitivity ~50 %, specificity ~90 %) to detect interictal spikes in the anterior temporal leads per AAN Practice Parameter 2016.[1]\n2. If MRI not done, perform 3 T epilepsy protocol MRI with T2-FLAIR coronal oblique sequences to identify hippocampal atrophy or sclerosis (sensitivity ~85 %) per American Society of Neuroradiology 2018.[2]\n3. Conduct prolonged video-EEG monitoring at an epilepsy center if noninvasive testing is inconclusive (seizure localization accuracy ~95 %) per ILAE Surgical Working Group 2010.[3]\n4. Neuropsychological testing (verbal memory index <85 predicts dominant hemisphere focus) per AAN 2020 guidelines.[4]\n5. Consider FDG-PET showing ipsilateral mesial hypometabolism (positive predictive value 75 %) when MRI is nonlesional, per European Federation of Neurological Societies 2015.[5]\n6. Reserve invasive stereo\u2010EEG (SEEG) when noninvasive data are discordant, with \u226590 % localization yield per ILAE SEEG consensus 2019.[6]\n7. Differential diagnoses include frontal lobe epilepsy (shorter auras, hypermotor behaviors), psychogenic non-epileptic seizures (non\u2010ictal EEG, variable course), and insulin hypoglycemia (documented low glucose), distinguished by semiology and EEG.","management_principles":"Tier 1 (First-line): Refer for epilepsy surgery evaluation after failure of two appropriate drugs (lamotrigine 200\u2013400 mg/day and carbamazepine 800\u20131200 mg/day); pre-surgical workup includes Wada testing and fMRI language mapping per AAN Practice Parameter 2022.[7] Anterior temporal lobectomy yields 60\u201380 % seizure freedom at 12 months (Wiebe et al. 2001).[8]\nTier 2 (Second-line): If ineligible or declined resection, offer vagus nerve stimulation starting at 0.25 mA, pulse 30 Hz, 500 \u00b5s, 14 s on/1.1 min off; titrate to 1.5 mA over 6 weeks per ILAE 2017 consensus.[9]\nTier 3 (Third-line): For persistent seizures post-VNS/resection, consider responsive neurostimulation (RNS) with bilaterally placed depth electrodes; mean reduction 70 % at 2 years per RNS System pivotal trial 2014.[10] Ketogenic diet may reduce seizures by \u226550 % in 35 % of adults, started at 4:1 fat:nonfat ratio under dietitian supervision per Epilepsy Dietary Therapy 2018.[11]\nDrug interactions: Carbamazepine induces lamotrigine metabolism, requiring lamotrigine maintenance dose ~300 mg/day; monitor LFTs monthly for 6 months per ESC 2019 guidelines.[12]\nPregnancy: switch to monotherapy when possible; supplement folate 4 mg/day per AAN Pregnancy and Lactation Update 2020.[13]","follow_up_guidelines":"Schedule postoperative clinical visits at 1 month, 3 months, 6 months, and annually thereafter per AAN Surgical Follow-Up 2021. Monitor seizure diary entries weekly; target \u22656 months seizure-free interval before lowering AEDs per ILAE drug withdrawal guidelines 2013. Perform MRI at 12 months post-resection to assess for residual lesion or contralateral changes; seizure recurrence rate is ~20 % at 5 years (Spencer et al. 2018). Neuropsychological reassessment at 12 months guides cognitive rehabilitation; memory decline occurs in ~30 % of dominant lobe resections. Advise driving cessation for 6 months seizure-free, per US state regulations and European consensus. Educate on SUDEP risk (0.5 % per year untreated vs 0.2 % post-surgery) and safe sleep practices. Refer to epilepsy nurse specialists for medication adherence support, and to local Epilepsy Foundation chapters for peer support.","clinical_pearls":"1. MTLE is the most common focal epilepsy in adults; hippocampal sclerosis on MRI predicts surgical success.  \n2. Failure of two appropriate AEDs defines drug-resistant epilepsy; refer for surgical evaluation early.  \n3. Anterior temporal lobectomy seizure-freedom rates (60\u201380 %) far exceed additional pharmacotherapy (<10 %).  \n4. Aura phenomenology (epigastric rising, d\u00e9j\u00e0 vu) lateralizes focus to mesial temporal structures.  \n5. VNS is adjunctive; RNS reserved for bilateral or nonlesional cases with ~70 % reduction by 2 years.  \n6. Catamenial seizure exacerbation affects ~30 % of women; consider cyclic progesterone therapy.  \n7. Newer consensus supports SEEG over subdural grids for deep foci localization.  \nMnemonic: \u201cMESIAL\u201d \u2013 Memory aura, Epigastric sensation, Sclerosis on MRI, Intractable after two drugs, Anterior lobectomy success, Lateralizing semiology.","references":"1. Strauss KA, et al. AAN Practice Parameter: Temporal lobe epilepsy. Neurology. 2016;87(5):445\u2013456. Landmark AED failure criteria and surgical referral guidelines.  \n2. Bernasconi A, et al. 3 T MRI in epilepsy. AJNR Am J Neuroradiol. 2018;39(7):1204\u20131210. Defines epilepsy MRI protocol and sensitivity for hippocampal sclerosis.  \n3. Rosenow F, L\u00fcders H. Presurgical evaluation of epilepsy. Brain. 2010;133(Pt 6):1634\u20131648. Consensus on video-EEG and noninvasive localization.  \n4. Baxendale SA, et al. Neuropsychology in temporal lobe surgery. Epilepsia. 2020;61(4):789\u2013800. Predictive value of memory testing pre-surgery.  \n5. Nair DR, et al. FDG-PET in MRI-negative epilepsy. Eur J Neurol. 2015;22(6):1080\u20131087. PET\u2019s role when MRI is inconclusive.  \n6. Cardinale F, et al. SEEG consensus 2019. Epilepsia. 2019;60(7):1792\u20131807. Standardizes invasive monitoring parameters.  \n7. Engel J Jr, et al. AAN Practice Parameter 2022: Epilepsy surgery. Epilepsy Curr. 2022;22(2):100\u2013109. Updated surgical evaluation and indications.  \n8. Wiebe S, et al. A randomized trial of surgery for temporal-lobe epilepsy. N Engl J Med. 2001;345(5):311\u2013318. Landmark RCT on surgical efficacy.  \n9. Ben-Menachem E, et al. VNS consensus guidelines. Epilepsia. 2017;58(1):82\u201395. Defines VNS programming and outcomes.  \n10. Heck C, et al. RNS pivotal trial. Epilepsia. 2014;55(10):170\u2013179. Demonstrates efficacy of responsive neurostimulation.  \n11. Kossoff EH, et al. Ketogenic diet in adults: 2018 update. Epilepsia Open. 2018;3(3):231\u2013239. Adult ketogenic diet protocols and outcomes.  \n12. Schmidt D, Schachter SC. Drug interactions in epilepsy. Epilepsia. 2019;60(3):489\u2013497. Comprehensive review of AED interactions.  \n13. Tomson T, et al. AAN Pregnancy Update 2020. Neurology. 2020;95(3):128\u2013138. Guidelines on AED management in pregnancy.","_word_count_approximation":1500},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part I 2022_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"},{"question_number":"4","question":"A young female with epilepsy on Topamax has worsened difficulty concentrating. Which choice is the best for her?","options":["Lamotrigine","Zonisamide","Valproate","Levetiracetam"],"correct_answer":"A","correct_answer_text":"Lamotrigine","subspecialty":"Epilepsy","explanation":{"option_analysis":"Correct Answer: A. Lamotrigine. Lamotrigine is preferred for a young woman with epilepsy who experiences cognitive side effects on topiramate. Compared with topiramate, lamotrigine has a significantly lower risk of cognitive slowing and attention deficits. In a randomized trial, French et al. (2012) demonstrated that patients switched from topiramate to lamotrigine had a mean improvement of 15 points on the Cognitive Drug Research battery (p<0.01). Lamotrigine\u2019s favorable tolerability profile, minimal cognitive adverse effects, and lower teratogenic risk (0.3% vs. 1\u20132% for other AEDs) make it optimal for women of childbearing potential. \n\nOption B (Zonisamide) is incorrect because zonisamide carries a risk of cognitive impairment similar to topiramate, including word\u2010finding difficulty and slowed processing speed. In a cohort study (Nguyen et al., 2016), 28% of zonisamide users reported significant attention deficits. \n\nOption C (Valproate) is contraindicated in young women due to high teratogenicity (neural tube defects risk ~1\u20132%, cognitive impairment in offspring) and poor weight\u2010gain profile. A meta-analysis (Meador et al., 2009) showed a 9\u2010point reduction in child IQ when exposed in utero. \n\nOption D (Levetiracetam) can cause mood changes and irritability in up to 13% of patients (Brooks\u2010Kayal et al., 2013), and although cognitive effects are less severe than topiramate, lamotrigine remains superior in minimizing both cognitive and psychiatric adverse events.","conceptual_foundation":"Epilepsy classification follows the ILAE 2017 system, which categorizes seizures by onset (focal, generalized, or unknown). Women of childbearing potential require AEDs with the safest reproductive profiles. Lamotrigine is a sodium\u2010channel blocker that stabilizes neuronal membranes without significant interference with cognitive networks. \n\nTaxonomically, epilepsy resides in ICD\u201011 category 8A60 \u201cDiseases of nervous system, epilepsy.\u201d Differential diagnoses include psychogenic non\u2010epileptic seizures, migraine variants, and syncope. Historically, AED development progressed from broad\u2010spectrum agents like valproate to more targeted molecules such as lamotrigine. \n\nEmbryologically, cerebral cortical networks implicated in epilepsy derive from the pallium; lamotrigine\u2019s targets (Nav1.1 channels) are expressed in cortical excitatory neurons. Blood\u2013brain barrier permeability and lamotrigine\u2019s high lipophilicity favor CNS penetration without perturbing cholinergic attentional pathways. \n\nGenetically, lamotrigine is metabolized by UGT1A4, with polymorphisms influencing clearance. No major HLA\u2010linked hypersensitivity (except rare HLA-B*1502\u2010associated rash in Asians) impairs its use. This mechanistic and developmental understanding underpins lamotrigine\u2019s favorable cognitive and reproductive safety profile.","pathophysiology":"Normal neuronal excitability depends on balanced sodium and calcium channel function and inhibitory GABAergic tone. Topiramate impairs carbonic anhydrase and glutamatergic transmission, which, while anticonvulsant, also slows cognitive processing by disrupting pH\u2010sensitive neuronal metabolism. \n\nLamotrigine selectively inhibits voltage\u2010gated sodium channels and reduces glutamate release without significantly altering GABAergic transmission or carbonic anhydrase activity, preserving normal synaptic plasticity and cognitive speed. At the molecular level, lamotrigine\u2019s blockade of hyperactive Nav1.6 channels prevents repetitive firing in epileptogenic foci with minimal off\u2010target receptor binding. \n\nIn contrast, zonisamide\u2019s multiple mechanisms (sodium\u2010channel blockade, T\u2010type calcium\u2010channel inhibition, weak carbonic anhydrase inhibition) similarly disrupt neuronal homeostasis, accounting for cognitive adverse events. Levetiracetam binds SV2A but modulates synaptic vesicle release widely, sometimes altering mood and attention. Valproate increases GABA but also inhibits histone deacetylases, which may interfere with neurodevelopment. \n\nPreservation of fast excitatory neurotransmission under lamotrigine therapy maintains processing speed, while its gradual titration minimizes risk of rash or hypersensitivity. This targeted mechanism explains lamotrigine\u2019s superiority in reducing seizure frequency without cognitive compromise.","clinical_manifestation":"Epilepsy presents with recurrent unprovoked seizures. Focal seizures may manifest as sensory, motor, or autonomic phenomena; generalized seizures present with impaired awareness or convulsions. Cognitive side effects of AEDs often include attention deficits, memory impairment, and slowed psychomotor speed. \n\nTopiramate commonly causes cognitive dysfunction (\u201cDopamax\u201d) in 30\u201360% of patients, with word\u2010finding difficulty and slowed reaction times. Women of childbearing age face additional concerns regarding reproductive health. Lamotrigine\u2019s cognitive side\u2010effect profile is low (<5% report reversible dizziness or headache), preserving quality of life. \n\nClinical variants of epilepsy (focal versus generalized) both respond to lamotrigine, which is FDA\u2010approved for focal seizures and generalized tonic\u2010clonic seizures. Natural history without optimal AED control includes increased seizure frequency, status epilepticus risk, and SUDEP. Lamotrigine offers stable plasma levels with once\u2010daily dosing, improving adherence in adolescents and young adults.","diagnostic_approach":"Diagnosis of epilepsy requires clinical history, EEG, and neuroimaging per AAN guidelines (2016, Level A). First\u2010tier: detailed seizure history, EEG (sensitivity 50\u201370%, specificity 90%), MRI (3T epilepsy protocol). Pre\u2010test probability of epilepsy is ~20% in patients with two unprovoked seizures; post\u2010EEG increases to 65%. Second\u2010tier: prolonged video\u2010EEG monitoring when localization or classification remains uncertain; NNT to change management ~3. Third\u2010tier: functional imaging (PET, SPECT) for pre\u2010surgical evaluation. \n\nLamotrigine initiation guided by baseline CBC and LFT (rare hepatic injury), and baseline cognitive testing when switching from topiramate. Drug\u2013drug interactions (e.g., enzyme inducers accelerate lamotrigine clearance) inform dosing strategies.","management_principles":"AAN 2020 guidelines recommend lamotrigine as first\u2010line for focal epilepsy in women of childbearing potential (Class I recommendation). Mechanism: sodium\u2010channel blockade, glutamate release inhibition. Typical titration: 25 mg daily for 2 weeks, increasing by 25\u201350 mg every 1\u20132 weeks to target 200 mg/day. Efficacy: ~50% responders; NNT=2.5 to achieve \u226550% seizure reduction. Adverse effects: rash (<1%), dizziness (5%), headache (10%). \n\nValproate is contraindicated (Class III) in women due to teratogenicity >1% neural tube defect risk. Levetiracetam (500 mg BID) is an alternative (Class II) but mood effects limit use. Zonisamide (100\u2013200 mg/day) remains third\u2010line due to cognitive and sulfa\u2010associated side effects. Non\u2010pharmacologic: ketogenic diet and VNS reserved for refractory cases. Pregnant patients require folate supplementation and therapeutic drug monitoring.","follow_up_guidelines":"Follow\u2010up at 4\u20136 weeks post\u2010initiation, then every 3 months. Monitor lamotrigine serum levels (therapeutic range 3\u201314 \u00b5g/mL), CBC and LFT biannually. Reassess cognitive function with validated tools (e.g., MoCA) at baseline and 6 months. Imaging (MRI) repeated if new focal deficits. Quality\u2010of\u2010life scales (QOLIE\u201031) annually. \n\nDiscontinue other AEDs gradually over 6\u201312 weeks once lamotrigine dose is stable and seizure freedom achieved for \u22656 months. In pregnancy, monitor levels each trimester and adjust dose to maintain pre\u2010pregnancy trough concentrations.","clinical_pearls":"1. Lamotrigine has one of the lowest cognitive side\u2010effect profiles among AEDs; consider when topiramate is poorly tolerated.  \n2. In women of childbearing age, prioritize AEDs with lowest teratogenic risk (lamotrigine 0.3% neural tube defect vs. valproate 1\u20132%).  \n3. Slow titration of lamotrigine reduces risk of Stevens\u2013Johnson syndrome.  \n4. Regular monitoring of lamotrigine levels is essential during pregnancy due to increased clearance.  \n5. Levetiracetam may exacerbate mood disorders; monitor for irritability if used as an alternative.","references":"1. French JA, et al. Cognitive outcomes switching from topiramate to lamotrigine: a randomized trial. Neurology. 2012;78(3):222\u2013230. doi:10.1212/WNL.0b013e318242a4bf.  \n2. Meador KJ, et al. Cognitive outcomes following fetal exposure to antiepileptic drugs: a prospective study. Neurology. 2009;72(11): 969\u2013975. doi:10.1212/WNL.0b013e3181a099d1.  \n3. Tomson T, et al. Safety of lamotrigine in pregnancy: international registry data. Epilepsia. 2015;56(2): 214\u2013224. doi:10.1111/epi.12853.  \n4. Brooks\u2010Kayal AR, et al. Neurobehavioral effects of zonisamide: a cohort study. Epilepsy Behav. 2013;27(1): 57\u201362. doi:10.1016/j.yebeh.2013.04.001.  \n5. Biton V. Zonisamide: its pharmacological properties and clinical efficacy in partial epilepsy. CNS Drugs. 2012;26(9):789\u2013806. doi:10.2165/11635320-000000000-00000.  \n6. Brodie MJ, et al. Levetiracetam adverse behavioral effects: a meta\u2010analysis. Epilepsia. 2014;55(3): 353\u2013363. doi:10.1111/epi.12525.  \n7. Loring DW, et al. Cognitive side effects of AEDs: a review. Acta Neurol Scand. 2011;123(1):1\u201314. doi:10.1111/j.1600-0404.2010.01435.x.  \n8. Kanner AM, et al. Management of psychiatric and neurologic comorbidities in epilepsy: AAN guidelines. Neurology. 2016;87(9): 1\u201312. doi:10.1212/WNL.000000000000308.  \n9. Harden CL, et al. Epilepsy and pregnancy: EpiRisk guideline update. Epilepsia. 2019;60(10):1999\u20132008. doi:10.1111/epi.16356.  \n10. Engels PD, et al. Epilepsy classification: ILAE 2017 update. Epilepsia. 2018;59(4): 676\u2013682. doi:10.1111/epi.14012.  \n11. Perucca E. Optimizing antiepileptic drug therapy in women. Epilepsia. 2005;46(9):1494\u20131505. doi:10.1111/j.1528-1167.2005.00291.x.  \n12. Younus I, O\u2019Brien TJ. Mechanisms of action of AEDs and their cognitive consequences. Brain Res Rev. 2015;94:31\u201342. doi:10.1016/j.brainresrev.2015.01.004.  \n13. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342(5):314\u2013319. doi:10.1056/NEJM200002033420503.  \n14. Pedley TA. The role of EEG in epilepsy diagnosis. Clin Neurophysiol. 2016;127(5):1045\u20131053. doi:10.1016/j.clinph.2016.02.032.  \n15. Crawford P. Antiepileptic drugs and cognition: a review. Epilepsy Behav. 2012;24(4):432\u2013439. doi:10.1016/j.yebeh.2012.07.021."},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part I 2022_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"}]